
Amy E. Armstrong
Pediatric oncologist and NF1 clinical trialist; Assistant Professor of Pediatrics at Washington University School of Medicine / St. Louis Children's Hospital, leading the pediatric solid tumor program.
5
APPEARANCES
5
PODCASTS
036
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
May 29, 2026
Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models
8:22
8:46
8:59

Angela HirbeGUEST
I mean, the skin manifestations here, so the cafele macules and the freckling, the mass on his hand also really clues me into this being NF1 and not one of the other neurocutaneous syndromes.

Amy E. ArmstrongGUEST
But really, the care of a patient with NF1 is very multidisciplinary, right? And that depends on what type of physical manifestations they have, what additional help they may need, and who needs to be part of that whole care team.

Amy E. ArmstrongGUEST
I feel like in pediatrics, we're pretty good about being the cornerstone of understanding what a patient may need and then getting everybody else involved to kind of jump on our train to provide the best care for the patients.
7 MINS LATER
Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models
8:22
8:46
8:59

Angela HirbeGUEST
I mean, the skin manifestations here, so the cafe de macules and the freckling, the mass on his hand also really clues me in to this being NF1 and not one of the other neurocutaneous syndromes.

Amy E. ArmstrongGUEST
But really, the care of a patient with NF1 is very multidisciplinary, right? And that depends on what type of physical manifestations they have, what additional help they may need, and who needs to be part of that whole care team.

Amy E. ArmstrongGUEST
I feel like in pediatrics, we're pretty good about being the cornerstone of understanding what a patient may need and then getting everybody else involved to kind of jump on our train to provide the best care for the patients.
7 MINS LATER
Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models
8:22
8:46
8:59

Angela HirbeGUEST
I mean, the skin manifestations here, so the cafe de macules and the freckling, the mass on his hand also really clues me in to this being NF1 and not one of the other neurocutaneous syndromes.

Amy E. ArmstrongGUEST
But really, the care of a patient with NF1 is very multidisciplinary, right? And that depends on what type of physical manifestations they have, what additional help they may need, and who needs to be part of that whole care team.

Amy E. ArmstrongGUEST
I feel like in pediatrics, we're pretty good about being the cornerstone of understanding what a patient may need and then getting everybody else involved to kind of jump on our train to provide the best care for the patients.
7 MINS LATER
Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models
8:22
8:46
8:59

Angela HirbeGUEST
I mean, the skin manifestations here, so the cafe de macules and the freckling, the mass on his hand also really clues me in to this being NF1 and not one of the other neurocutaneous syndromes.

Amy E. ArmstrongGUEST
But really, the care of a patient with NF1 is very multidisciplinary, right? And that depends on what type of physical manifestations they have, what additional help they may need, and who needs to be part of that whole care team.

Amy E. ArmstrongGUEST
I feel like in pediatrics, we're pretty good about being the cornerstone of understanding what a patient may need and then getting everybody else involved to kind of jump on our train to provide the best care for the patients.
7 MINS LATER
Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models
8:22
8:46
8:59

Angela HirbeGUEST
I mean, the skin manifestations here, so the cafele macules and the freckling, the mass on his hand also really clues me into this being NF1 and not one of the other neurocutaneous syndromes.

Amy E. ArmstrongGUEST
But really, the care of a patient with NF1 is very multidisciplinary, right? And that depends on what type of physical manifestations they have, what additional help they may need, and who needs to be part of that whole care team.

Amy E. ArmstrongGUEST
I feel like in pediatrics, we're pretty good about being the cornerstone of understanding what a patient may need and then getting everybody else involved to kind of jump on our train to provide the best care for the patients.
7 MINS LATER